[go: up one dir, main page]

PE20040845A1 - Compuestos calciliticos - Google Patents

Compuestos calciliticos

Info

Publication number
PE20040845A1
PE20040845A1 PE2003001196A PE2003001196A PE20040845A1 PE 20040845 A1 PE20040845 A1 PE 20040845A1 PE 2003001196 A PE2003001196 A PE 2003001196A PE 2003001196 A PE2003001196 A PE 2003001196A PE 20040845 A1 PE20040845 A1 PE 20040845A1
Authority
PE
Peru
Prior art keywords
propoxi
difluor
indan
hydroxy
phenyl
Prior art date
Application number
PE2003001196A
Other languages
English (en)
Inventor
Robert W Marquis
Linda N Casillas
Joshi M Ramanjulu
James Francis Callahan
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of PE20040845A1 publication Critical patent/PE20040845A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/28—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
    • C07C217/30—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/28—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
    • C07C217/30—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/32—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/28—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
    • C07C217/30—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/32—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
    • C07C217/34—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted by halogen atoms, by trihalomethyl, nitro or nitroso groups, or by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)

Abstract

SE REFIERE A COMPUESTOS DE FORMULA I DONDE R1 Y R5 SON H, HALO; R2, R3 Y R4 SON H, HALO Y J-K; DONDE J ES UN ENLACE COVALENTE, ALQUILENO O ALQUENILO Y K ES CO2R8; R8 ES H O ALQUILO; R6 ES H, ALQUILO; R7 ES ARILO, ARILO CONDENSADO, DIHIDRO, TETRAHIDRO ARILO CONDENSADO, HETEROARILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS CLORHIDRATO DE (E)-3-{3,4-DIFLUOR-5-[(R)-2-HIDROXI-3-(2-INDAN-2-IL-1,1-DIMETILETILAMINO)-PROPOXI]-FENIL}-ACRILICO, CLORHIDRATO DE ACIDO 3-{3,4-DIFLUOR-5-[(R)-2-HIDROXI-3-(2-INDAN-2-IL-1,1-DIMETILETILAMINO)-PROPOXI]-FENIL}-ACRILICO, CLORHIDRATO DE ESTER ETILICO DEL ACIDO 3-{3,4-DIFLUOR-5-[(R)-2-HIDROXI-3-(2-INDAN-2-IL-1,1-DIMETIL-ETIL-AMINO)-PROPOXI]-FENIL}-PENTANOICO, ENTRE OTROS. SE REFIERE TAMBIEN A COMPOSICIONES FARMACEUTICAS. LOS COMPUESTOS MENCIONADOS INHIBEN LA ACTIVIDAD DEL RECEPTOR DE CALCIO Y SON UTILES PARA EL TRATAMIENTO DE TRASTORNO OSEO COMO FRACTURAS, OSTEOARTRITIS, ARTRITIS REUMATOIDEA
PE2003001196A 2002-11-26 2003-11-25 Compuestos calciliticos PE20040845A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42910502P 2002-11-26 2002-11-26

Publications (1)

Publication Number Publication Date
PE20040845A1 true PE20040845A1 (es) 2004-11-28

Family

ID=32393505

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003001196A PE20040845A1 (es) 2002-11-26 2003-11-25 Compuestos calciliticos

Country Status (32)

Country Link
US (6) US7514473B2 (es)
EP (1) EP1569892B1 (es)
JP (1) JP4489597B2 (es)
KR (2) KR20050086786A (es)
CN (1) CN1325466C (es)
AP (1) AP2113A (es)
AR (1) AR042132A1 (es)
AU (1) AU2003291157C1 (es)
BR (1) BR0316544A (es)
CA (1) CA2507226C (es)
CO (1) CO5570664A2 (es)
CY (1) CY1113083T1 (es)
DK (1) DK1569892T3 (es)
EA (1) EA009603B1 (es)
ES (1) ES2388277T3 (es)
IL (1) IL168704A (es)
IS (1) IS2897B (es)
MA (1) MA27528A1 (es)
MX (1) MXPA05005574A (es)
MY (1) MY143244A (es)
NO (1) NO332304B1 (es)
NZ (1) NZ540275A (es)
OA (1) OA12962A (es)
PE (1) PE20040845A1 (es)
PL (1) PL211571B1 (es)
PT (1) PT1569892E (es)
SI (1) SI1569892T1 (es)
TW (1) TWI316511B (es)
UA (1) UA81642C2 (es)
UY (1) UY28089A1 (es)
WO (1) WO2004047751A2 (es)
ZA (1) ZA200504104B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY143244A (en) * 2002-11-26 2011-04-15 Smithkline Beecham Corp Calcilytic compounds
US7318925B2 (en) 2003-08-08 2008-01-15 Amgen Fremont, Inc. Methods of use for antibodies against parathyroid hormone
DE60325906D1 (de) 2003-08-08 2009-03-05 Amgen Fremont Inc Antikörper gegen parath-hormon (pth) und ihre verwendungen
US20070155819A1 (en) * 2004-02-06 2007-07-05 Marquis Robert W Jr Calcilytic compounds
TW200845956A (en) 2006-12-18 2008-12-01 Smithkline Beecham Corp Calcilytic compounds
PL2292592T3 (pl) * 2008-06-05 2013-01-31 Asahi Kasei Pharma Corp Związki sulfonamidowe i ich zastosowanie
SG172141A1 (en) * 2008-12-24 2011-07-28 Daiichi Sankyo Co Ltd Indanyl compounds
GB201217330D0 (en) 2012-09-28 2012-11-14 Univ Cardiff Therapeutic for treating inflammatory lung disorders
WO2015196205A1 (en) * 2014-06-20 2015-12-23 Glaxosmithkline Llc Method of using calcilytic compounds to treat diseases of abnormal glucose or insulin levels

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE298506C (es)
US643656A (en) * 1898-09-03 1900-02-20 Francis Keil Mold for lock-cylinders and key-hubs.
ES421076A1 (es) 1973-12-01 1976-04-01 Andreu Sa Dr Procedimiento para la obtencion de 1-ariloxi-3-aralquilami-no-2-propanoles.
ES442062A1 (es) 1975-10-24 1977-04-01 Andreu Sa Dr Procedimiento para la obtencion de 1-ariloxi-2-hidroxi-3- alquilaminopropanos.
DE2644833A1 (de) 1976-10-05 1978-04-20 Boehringer Sohn Ingelheim Neue 1-aryloxy-2-hydroxy-3-alkylenaminopropane und verfahren zu ihrer herstellung
CH618335A5 (es) * 1977-05-31 1980-07-31 Arnegger Richard E
US4234595A (en) * 1977-07-13 1980-11-18 Mead Johnson & Company 3-Indolyl-tertiary butylaminopropanols
IT1101724B (it) * 1978-12-05 1985-10-07 Erba Carlo Spa Derivati morfolinici e fenossiprofanolaminici e procedimento per la loro preparazione
IL56369A (en) 1978-01-20 1984-05-31 Erba Farmitalia Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them
GB2014968A (en) 1978-02-24 1979-09-05 Pearson J Article handling apparatus
US4495352A (en) 1979-02-13 1985-01-22 Mead Johnson & Company Heterocyclic substituted aryloxy 3-indolyl-tertiary butylaminopropanols
ES480066A1 (es) 1979-04-28 1980-04-01 Especialid Latin Medicam Unive Procedimiento de obtencion de 1-4-cloro-&,&-dimetil-benceno-etanamino-2-oxi-3 ariloxi propanos.
DE3544172A1 (de) 1985-12-13 1987-06-19 Lentia Gmbh Neue kristalline salze von aryloxy-propanolaminen, verfahren zu ihrer herstellung und ihre verwendung
FR2601008B1 (fr) 1986-07-03 1990-03-30 Sanofi Sa Procede de synthese stereospecifique de derives de l'indole
DD298506A5 (de) * 1988-12-30 1992-02-27 Ernst-Moritz-Arndt-Universitaet Greifswald,De Verfahren zur herstellung halogensubstituierter 1-phenoxy-3-alkylamino-propan-2-ole
DE4040186A1 (de) 1989-12-20 1991-06-27 Hoechst Ag Hypoglykaemisch aktive propandiolaminderivate mit insulin-aehnlicher wirkung und deren verwendung, neue propandiolaminderivate, diese substanzen enthaltende pharmazeutische zubereitungen und ihre verwendung zur behandlung von krankheiten
HN1996000101A (es) 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
US6818660B2 (en) 1996-04-09 2004-11-16 Nps Pharmaceuticals, Inc. Calcilytic compounds
NZ332068A (en) 1996-04-09 2001-03-30 Smithkline Beecham Alpha, alpha-disubstituted arylalkylamine derivatives as calcilytic compounds
US20020019440A1 (en) 1996-11-05 2002-02-14 Virbac Sa Aryloxypropanolamine derivatives, method of preparation and applications thereof
TW483881B (en) 1996-12-03 2002-04-21 Nps Pharma Inc Calcilytic compounds
US7202261B2 (en) 1996-12-03 2007-04-10 Nps Pharmaceuticals, Inc. Calcilytic compounds
CA2285556A1 (en) 1997-04-04 1998-10-15 Smithkline Beecham Corporation Calcilytic compounds
UY24949A1 (es) 1997-04-08 2001-04-30 Smithkline Beecham Corp Compuestos calcilíticos
DE19913753A1 (de) 1998-04-01 1999-10-07 Mannesmann Rexroth Ag Verfahren zur Bildung des Mittelwertes
PE20000415A1 (es) 1998-04-08 2000-05-21 Smithkline Beecham Corp Compuestos calciliticos
AR014975A1 (es) 1998-04-08 2001-04-11 Nps Pharma Inc Compuestos calciliticos, una composicion farmaceutica que los comprende, y el uso de los mismos para la fabricacion de un medicamento
CA2340341A1 (en) 1998-08-12 2000-02-24 Smithkline Beecham Corporation Calcilytic compounds
JP2002522499A (ja) 1998-08-12 2002-07-23 スミスクライン・ビーチャム・コーポレイション カルシウム分解化合物
PE20001456A1 (es) 1999-02-02 2001-01-28 Smithkline Beecham Corp Compuestos calcioliticos
WO2001007026A2 (en) 1999-07-22 2001-02-01 Eli Lilly And Company Improved method of treating type ii diabetes and obesity
CO5180628A1 (es) 1999-07-31 2002-07-30 Smithkline Beecham Corp Compuestos calcioliticos
US20030018203A1 (en) 2002-07-17 2003-01-23 Largo Maria Amparo Calcilytic compounds
AR030684A1 (es) * 2000-01-24 2003-09-03 Smithkline Beecham Corp Compuestos calciliticos, uso de dichos compuestos en la manufactura de medicamentos, e intermediarios utiles en la preparacion de dichos compuestos
WO2002007673A2 (en) 2000-07-21 2002-01-31 Smithkline Beecham Corporation Calcilytic compounds
JP2004514659A (ja) 2000-10-25 2004-05-20 スミスクライン・ビーチャム・コーポレイション カルシライティック化合物
MXPA03003688A (es) 2000-10-25 2003-08-07 Smithkline Beecham Corp Compuestos calciliticos.
WO2002072760A2 (en) * 2001-03-08 2002-09-19 Smithkline Beecham Corporation Pcra helicase inhibitors
US6864267B2 (en) 2001-07-16 2005-03-08 Smithkline Beecham Corporation Calcilytic compounds
MY143244A (en) 2002-11-26 2011-04-15 Smithkline Beecham Corp Calcilytic compounds
JP2006522160A (ja) 2003-04-07 2006-09-28 エヌピーエス ファーマスーティカルズ インコーポレイテッド ２，３，５，６−置換３ｈ−ピリミジン−４−オンの調製方法
WO2005018561A2 (en) 2003-08-20 2005-03-03 Nitromed, Inc. Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use
AR045799A1 (es) 2003-09-24 2005-11-16 Glaxo Group Ltd Compuesto 6- oxo-2,5- dioxabiciclico y su uso para preparar una composicion farmaceutica
WO2005030746A1 (en) 2003-09-24 2005-04-07 Glaxo Group Limited Calcilytic compounds
US20080234370A1 (en) 2004-02-06 2008-09-25 Marquis Robert W Calcilytic Compounds
NL1025457C1 (nl) 2004-02-11 2005-08-12 Rudolf Johannes Gerardus Hoorn Haspelrem.
AU2005304770A1 (en) 2004-11-08 2006-05-18 Nicox S.A. Nitrosated and nitrosylated compounds, compositions and methods for the treatment of ophthalmic disorders
AU2006206249A1 (en) 2005-01-21 2006-07-27 Nicox S.A. Cardiovascular compounds comprising heterocyclic nitric oxide donor group compositions and methods of use

Also Published As

Publication number Publication date
IS7880A (is) 2005-06-02
US20130158114A1 (en) 2013-06-20
NO20053071L (no) 2005-06-22
US9227914B2 (en) 2016-01-05
MA27528A1 (fr) 2005-09-01
HK1082914A1 (en) 2006-06-23
KR20110124806A (ko) 2011-11-17
US8399517B2 (en) 2013-03-19
US8586631B2 (en) 2013-11-19
CN1325466C (zh) 2007-07-11
US20150183723A1 (en) 2015-07-02
BR0316544A (pt) 2005-10-04
MY143244A (en) 2011-04-15
MXPA05005574A (es) 2005-07-27
US20110054021A1 (en) 2011-03-03
EA200500878A1 (ru) 2005-10-27
EP1569892A4 (en) 2010-09-15
CA2507226C (en) 2011-11-15
PL211571B1 (pl) 2012-05-31
TW200510276A (en) 2005-03-16
CN1741985A (zh) 2006-03-01
ZA200504104B (en) 2006-03-29
WO2004047751A2 (en) 2004-06-10
AU2003291157B2 (en) 2011-01-20
OA12962A (en) 2006-10-13
KR20050086786A (ko) 2005-08-30
US7514473B2 (en) 2009-04-07
AU2003291157A1 (en) 2004-06-18
EP1569892A2 (en) 2005-09-07
US8980950B2 (en) 2015-03-17
NO332304B1 (no) 2012-08-20
JP4489597B2 (ja) 2010-06-23
TWI316511B (en) 2009-11-01
EA009603B1 (ru) 2008-02-28
US7829594B2 (en) 2010-11-09
EP1569892B1 (en) 2012-06-13
US20090163589A1 (en) 2009-06-25
JP2006507348A (ja) 2006-03-02
AP2113A (en) 2010-03-04
KR101142697B1 (ko) 2012-05-10
CA2507226A1 (en) 2004-06-10
SI1569892T1 (sl) 2012-09-28
US20060058391A1 (en) 2006-03-16
PL376965A1 (pl) 2006-01-09
AU2003291157C1 (en) 2011-05-12
UA81642C2 (ru) 2008-01-25
WO2004047751A3 (en) 2004-08-19
US20140057980A1 (en) 2014-02-27
ES2388277T3 (es) 2012-10-11
CY1113083T1 (el) 2016-04-13
NZ540275A (en) 2007-11-30
CO5570664A2 (es) 2005-10-31
AR042132A1 (es) 2005-06-08
AP2005003320A0 (en) 2005-06-30
PT1569892E (pt) 2012-09-06
DK1569892T3 (da) 2012-08-27
UY28089A1 (es) 2004-06-30
IL168704A (en) 2010-12-30
IS2897B (is) 2014-09-15

Similar Documents

Publication Publication Date Title
UY30620A1 (es) Derivados de piridido[4,3-d]pirimidin-4(3h)-ona como antagonistas de los receptores de calcio
PE20030010A1 (es) Triazolopiridinas como inhibidores de quinasas
PE20040845A1 (es) Compuestos calciliticos
DOP2001000271A (es) Compuestos de imidazol condensado con arilo o heteroarilo como agentes antiinflamatorios y analgésicos.
CY1110952T1 (el) Παραγωγα κινουκλιδινης και η χρηση αυτων ως μουσκαρινικοι ανταγωνιστες υποδοχεων μ3
UY27154A1 (es) Pirimidinas inhibidoras de metaloproteinasa de matriz
CA2816000A1 (en) Drug derivatives
UY27882A1 (es) Compuestos quimicos
GT200100160A (es) Derivados 4-fenil-piridina.
BR0108610A (pt) Compostos azapolicìclicos condensados com arila
AR077267A1 (es) Derivados nitrogenados heterociclicos inhibidores selectivos de pi3k, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades inflamatorias y/o autoinmunes.
PE20051155A1 (es) Compuestos de imidazol para el tratamiento de trastornos neurodegenerativos
NO20025641D0 (no) Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister
PE20091444A1 (es) Derivados de isoxazolo-pirazina
MXPA05007494A (es) Nuevos compuestos.
NO20025640D0 (no) Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister
PE20030127A1 (es) Derivados de acido sulfonico
GT200000197A (es) 2-(3,5-bis-trifluorometil-fenil)-n-metil-n-(6- morfolin-4-il-4-o tolil-piridin-3-il)-isobutiramida.
PE34297A1 (es) Ligandos especificos del neuropeptido y1
PE20030563A1 (es) Agentes antidiabeticos
PA8575001A1 (es) Fluorobenzamidas como inhibidores de maob
AR050914A1 (es) Agonista receptor de vasopresina peptidico
CO5160251A1 (es) Analogos de prostaglandinas selectivos del receptor fp c16 insaturados
AR064406A1 (es) Compuesto de (halo-alquilcarboxi-fenil)-hidroxietilamina composicion farmaceutica que lo comprende su uso para preparar un medicamento, metodo para sintetizar dicho compuesto y compuesto intermedio correspondiente
CO5150190A1 (es) Nuevos analogos de prostaglandina f que ocurren naturalmente y metodos de utilizar tales nuevos analogos de prostaglandina f

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed